The Platelet PGD test, which previously received 510 (k) clearance from the FDA holds potential to improve the safety of the blood supply by easily and quickly detecting a broad range of bacterial contaminants, the company said.
The Platelet PGD test has now demonstrated the ability to reliably detect a broad variety of common bacterial contaminants in buffy coat platelets. The test is based on Verax Biomedical’s proprietary PGD bacterial detection technology, which targets common antigens found on the surface of all species of bacteria known to be pathogenic to humans.
Jim Lousararian, CEO of Verax Biomedical, said: “CE marking of the Platelet PGD test is an important step in improving blood safety on a global level. We believe this test, and the technology it is founded on, are critical tools in the battle against bacterial contamination.”